Biodegradable interstitial release polymer loading a novel small molecule targeting Axl receptor tyrosine kinase and reducing brain tumour migration and invasion

Oncogene

Volumn 35, Issue 17, 2016, Pages 2156-2165

  Yen, S Y ^a   Chen, S R ^a   Hsieh, J ^b   Li, Y S ^a   Chuang, S E ^c   Chuang, H M ^d   Huang, M H ^d   Lin, S Z ^e,f,g   Harn, H J ^e,f   Chiou, T W ^a  

^a NATIONAL DONG HWA UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g CHINA MEDICAL UNIVERSITY BEIGANG HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BIS(4 CARBOXYPHENOXY)PROPANE CO SEBACIC ACID; ANTINEOPLASTIC AGENT; AXL RECEPTOR TYROSINE KINASE; BUTYLIDENEPHTHALIDE; GELATINASE A; MITOGEN ACTIVATED PROTEIN KINASE; POLYANHYDRIDE; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; ONCOPROTEIN; PHTHALIC ANHYDRIDE; POLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG BRAIN LEVEL; DRUG DIFFUSION; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; GENE REPRESSION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR INVASION; ANIMAL; BIOSYNTHESIS; CELL MOTION; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METASTASIS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; DRUG DELIVERY SYSTEMS; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PHTHALIC ANHYDRIDES; POLYMERS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938891691     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.277     Document Type: Article

References (30)

1. Jelsma R, Bucy PC. The treatment of glioblastoma multiforme of the brain. J Neurosurg 1967; 27: 388-400.
2. Tsitlakidis A, Foroglou N, Venetis CA, Patsalas I, Hatzisotiriou A, Selviaridis P. Biopsy versus resection in the management of malignant gliomas: a systematic review and meta-analysis. J Neurosurg 2010; 112: 1020-1032.
3. Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003; 21: 1624-1636.
4. Blacklock JB, Wright DC, Dedrick RL, Blasberg RG, Lutz RJ, Doppman JL et al. Drug streaming during intra-arterial chemotherapy. J Neurosurg 1986; 64: 284-291.
5. Shapiro WR, Green SB. Reevaluating the efficacy of intra-arterial BCNU. J Neuro-surg 1987; 66: 313-315.
6. Elliott PJ, Hayward NJ, Huff MR, Nagle TL, Black KL, Bartus RT. Unlocking the blood-brain barrier: a role for RMP-7 in brain tumor therapy. Exp Neurol 1996; 141: 214-224.
7. Keating AK, Kim GK, Jones AE, Donson AM, Ware K, Mulcahy JM et al. Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Mol Cancer Ther 2010; 9: 1298-1307.
8. Linger RM, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res 2008; 100: 35-83.
9. Pierce AM, Keating AK. TAM receptor tyrosine kinases: expression, disease and oncogenesis in the central nervous system. Brain Res 2014; 1542: 206-220.
10. Verma A, Warner SL, Vankayalapati H, Bearss DJ, Sharma S. Targeting Axl and Mer kinases in cancer. Mol Cancer Ther 2011; 10: 1763-1773.
11. Lemke G, Rothlin CV. Immunobiology of the TAM receptors. Nat Rev Immunol 2008; 8: 327-336.
12. Bezbradica JS, Medzhitov R. Integration of cytokine and heterologous receptor signaling pathways. Nat Immunol 2009; 10: 333-339.
13. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009; 28: 15-33.
14. Mejlvang J, Kriajevska M, Vandewalle C, Chernova T, Sayan AE, Berx G et al. Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. Mol Biol Cell 2007; 18: 4615-4624.
15. Puisieux A, Brabletz T, Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol 2014; 16: 488-494.
16. Hutterer M, Knyazev P, Abate A, Reschke M, Maier H, Stefanova N et al. Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin Cancer Res 2008; 14: 130-138.
17. Gjerdrum C, Tiron C, Hoiby T, Stefansson I, Haugen H, Sandal T et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci USA 2010; 107: 1124-1129.
18. Asiedu MK, Beauchamp-Perez FD, Ingle JN, Behrens MD, Radisky DC, Knutson KL. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene 2014; 33: 1316-1324.
19. Lin PC, Chen YL, Chiu SC, Yu YL, Chen SP, Chien MH et al. Orphan nuclear receptor, Nurr-77 was a possible target gene of butylidenephthalide chemotherapy on glioblastoma multiform brain tumor. J Neurochem 2008; 106: 1017-1026.
20. Tsai NM, Lin SZ, Lee CC, Chen SP, Su HC, Chang WL et al. The antitumor effects of Angelica sinensis on malignant brain tumors in vitro and in vivo. Clin Cancer Res 2005; 11: 3475-3484.
21. Tsai NM, Chen YL, Lee CC, Lin PC, Cheng YL, Chang WL et al. The natural compound n-butylidenephthalide derived from Angelica sinensis inhibits malignant brain tumor growth in vitro and in vivo. J Neurochem 2006; 99: 1251-1262.
22. Lin PC, Lin SZ, Chen YL, Chang JS, Ho LI, Liu PY et al. Butylidenephthalide suppresses human telomerase reverse transcriptase (TERT) in human glioblastomas. Ann Surg Oncol 2011; 18: 3514-3527.
23. Huang MH, Lin SZ, Lin PC, Chiou TW, Harn YW, Ho LI et al. Brain tumor senescence might be mediated by downregulation of S-phase kinase-associated protein 2 via butylidenephthalide leading to decreased cell viability. Tumour Biol 2014; 35: 4875-4884.
24. Harn HJ CS, Huang MH, Lin PC, Syu FJ et al. (Z)-Butylidenephthalide restores temozo-lomide sensitivity to temozolomide-resistant malignant glioma cells by downregulating expression of the DNA repair enzyme MGMT. J Pharmacy Pharmacol 2013; 1: 36-49.
25. Harn HJ, Lin SZ, Lin PC, Liu CY, Liu PY, Chang LF et al. Local interstitial delivery of z-butylidenephthalide by polymer wafers against malignant human gliomas. Neuro-oncology 2011; 13: 635-648.
26. Volk-Draper L, Hall K, Griggs C, Rajput S, Kohio P, DeNardo D et al. Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner. Cancer Res 2014; 74: 5421-5434.
27. Rajput S, Volk-Draper LD, Ran S. TLR4 is a novel determinant of the response to paclitaxel in breast cancer. Mol Cancer Ther 2013; 12: 1676-1687.
28. Holland EC. Glioblastoma multiforme: the terminator. Proc Natl Acad Sci USA 2000; 97: 6242-6244.
29. Vajkoczy P, Knyazev P, Kunkel A, Capelle HH, Behrndt S, von Tengg-Kobligk H et al. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci USA 2006; 103: 5799-5804.
30. Domb AJ, Langer R, Polyanhydrides I. Preparation of high molecular weight polyanhydrides. J Polymer Sci A Polymer Chem 1987; 25: 3373-3386.